Xeris Biopharma Holdings Inc XERS Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Mar 18, 2024 (filed on Mar 18, 2024)

Insider Name:

Johnson John

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-215,600

Price:

--
Mar 18, 2024 (filed on Mar 18, 2024)

Insider Name:

Johnson John

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

215,600

Price:

$1.99
Mar 15, 2024 (filed on Apr 11, 2024)

Insider Name:

Sherman Jeffrey W

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

6,502

Price:

--
Mar 15, 2024 (filed on Apr 01, 2024)

Insider Name:

Kong Garheng

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

6,474

Price:

--
Mar 15, 2024 (filed on Apr 01, 2024)

Insider Name:

Johnson John

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

89,571

Price:

--
Mar 14, 2024 (filed on Mar 14, 2024)

Insider Name:

Schmid John P.

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

4,500

Price:

$2.16
Jan 31, 2024 (filed on Jan 31, 2024)

Insider Name:

Pieper Steven

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

450,000

Price:

--
Jan 31, 2024 (filed on Jan 31, 2024)

Insider Name:

Shannon John Patrick Jr

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

750,000

Price:

--
Jan 31, 2024 (filed on Jan 31, 2024)

Insider Name:

Johnson Kenneth Erland

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

175,000

Price:

--
Jan 31, 2024 (filed on Jan 31, 2024)

Insider Name:

Hecht Beth

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

750,000

Price:

--

Filings by filing date

Mar 15, 2024 (filed on Apr 11, 2024)

Insider Name:

Sherman Jeffrey W

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

6,502

Price:

--
Mar 15, 2024 (filed on Apr 01, 2024)

Insider Name:

Kong Garheng

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

6,474

Price:

--
Mar 15, 2024 (filed on Apr 01, 2024)

Insider Name:

Johnson John

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

89,571

Price:

--
Mar 18, 2024 (filed on Mar 18, 2024)

Insider Name:

Johnson John

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-215,600

Price:

--
Mar 18, 2024 (filed on Mar 18, 2024)

Insider Name:

Johnson John

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

215,600

Price:

$1.99
Mar 14, 2024 (filed on Mar 14, 2024)

Insider Name:

Schmid John P.

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

4,500

Price:

$2.16
Jan 31, 2024 (filed on Jan 31, 2024)

Insider Name:

Pieper Steven

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

450,000

Price:

--
Jan 31, 2024 (filed on Jan 31, 2024)

Insider Name:

Shannon John Patrick Jr

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

750,000

Price:

--
Jan 31, 2024 (filed on Jan 31, 2024)

Insider Name:

Johnson Kenneth Erland

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

175,000

Price:

--
Jan 31, 2024 (filed on Jan 31, 2024)

Insider Name:

Hecht Beth

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

750,000

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Pharmaceuticals

See Regulatory Filings on SEC

Company Contact

Address:	1375 West Fulton Street, Suite 1300 CHICAGO IL 60607
Tel:	1-844-4455704
Website:	https://www.xerispharma.com
IR:	See website

Key People

Paul Raymond Edick Chairman of the Board, Chief Executive Officer	John P. Shannon President, Chief Operating Officer	Steven M. Pieper Chief Financial Officer
Kenneth Erland Johnson Senior Vice President - Global Development and Medical Affairs	Steven Prestrelski Chief Scientific Officer	Beth P. Hecht Chief Legal Officer, Corporate Secretary

Business Overview

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patients' lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). It also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. Its product candidate XP-8121, which is designed to be a once-weekly, small-volume, subcutaneous injection that bypasses the gastrointestinal tract and could avoid many therapeutic complications.

Financial Overview

For the fiscal year ended 31 December 2023, Xeris Biopharma Holdings Inc revenues increased 49% to $163.9M. Net loss decreased 34% to $62.3M. Revenues reflect Product revenue -Recorlev segment increase from $7.4M to $29.5M, Product revenue - Gvoke segment increase of 28% to $67M. Lower net loss reflects Change in fair value of contingent value increase from $3.2M (expense) to $5.2M (income).

Employees:	377 as of Dec 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$365.68M as of Dec 31, 2023
Annual revenue (TTM):	$163.91M as of Dec 31, 2023
EBITDA (TTM):	-$31.57M as of Dec 31, 2023
Net annual income (TTM):	-$62.26M as of Dec 31, 2023
Free cash flow (TTM):	-$49.29M as of Dec 31, 2023
Net Debt Last Fiscal Year:	$118.48M as of Dec 31, 2023
Shares outstanding:	140,453,467 as of Feb 29, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization